The “Skinny” on Weight Loss Drugs
November 2023
A lot of attention has been given lately to a new class of drugs called GLP-1’s. These drugs are increasingly being prescribed for type 2 diabetes and weight loss. Most Crystal Clear Rx clients cover these drugs for diabetes, but more and more Plan Sponsors are asking whether they should also cover these drugs for weight loss?
Obesity is a real problem in the U.S. today. According to the CDC, over 40% of American adults are obese. Obesity contributes to many health-related conditions such as type 2 diabetes, cardiovascular disease, stroke, musculoskeletal disorders and so on. These conditions drive pharmacy and medical costs for Plan Sponsors. Therefore, it makes perfect sense for Plans to consider what they can do to help their members control and maintain a healthy weight.
Many Plans currently only cover these drugs for members who are already using other, diabetic products. In other words, the Plan covers these drugs only for people diagnosed with diabetes. But does it make sense to cover these drugs for obesity? At an average cost of around $1,000 per month, this therapy is not inexpensive. So, will the Plan realize any financial benefits for covering the cost of these drugs?
Studies are showing significant health improvements for patients who have lost weight due to the use of a GLP-1 drug. These studies also report that there are some minor side-effects that can be troublesome but are generally controllable. There is a very slight risk of more serious side-effects, but these are rare. In discussing this with some industry experts, we expect to see a continued increase in the prescribing of these drugs as time goes on, and as more and more data continues to show very positive results from these products.
Data shows that patients who are prescribed a GLP-1 drug can lose 15-20% of their body weight, or even more in some cases. However, some sources report that these drugs do not work for everyone. And there is some data that shows that once patients discontinue taking these drugs, they often regain all the weight they previously lost. Lifestyle changes remain an important necessity in maintaining a healthy weight, and relying solely on a drug for positive results is not ideal.
So, should CCRx clients begin covering GLP-1 medications for the treatment of obesity? This may cause an increase in Rx costs initially, but in the longer term we hope and expect to see a reduction in both pharmacy and medical costs for diabetes and other weight-related conditions.
We expect more and more pressure on Plans to begin covering these medications. Plans may want to establish certain criteria that must be met to get approval from the Plan to cover these drugs. For example, some plans will only cover these drugs for the indication of weight loss if the member has a BMI of 30 or above, or 27 and above in combination with a serious, health risk such as high blood pressure, or high cholesterol. The Plan may also wish to require continued weight loss over time as a criterion for ongoing coverage of the product.
If you have questions about weight loss drugs or would like our help in developing Prior Authorization criteria to manage these products, please contact your CCRx Consultant.
Recent Newsletters
FTC Complaint Against the Three Largest Pharmacy Benefit Managers
FTC Complaint Against the Three Largest Pharmacy Benefit Managers September 2024The recent Federal Trade Commission (FTC) complaint against the three largest pharmacy benefit managers (PBMs) has brought critical issues surrounding insulin pricing and patient access to...
Managing the Costs of GLP-1 Drugs: A Strategic Approach
Managing the Costs of GLP-1 Drugs: A Strategic Approach June 2024At Crystal Clear Rx (CCRx), we understand that the rising popularity and costs of GLP-1 drugs have raised many questions and concerns. We aim to provide clarity and guidance on managing these expenses...
What Is The Right Copay Strategy?
What Is The Right Copay Strategy? January 2024Crystal Clear Rx clients know that effectively managing the pharmacy benefit involves more than just PBM pricing. Utilization, Drug Mix, and Plan Design also impact the amount of money the Plan spends on their pharmacy...
What to look for in a pharmacy benefit consultant
What to look for in a Pharmacy Benefit Consultant November 21, 2023Nobody wants to pay more than they should for any product or service. So, when many companies become concerned over pharmacy benefit costs, they may look for a Pharmacy Benefits Consultant or firm who...
Walgreens and CVS pharmacist Walk-outs
Walgreens and CVS pharmacist Walk-outs October 30th, 2023You may have recently seen news stories regarding pharmacist walk-outs at both Walgreens and CVS, and the potential for further work stoppages in the future at both of these companies, and potentially at other...
Choosing a PBM
Choosing a PBM September 2023 One of the primary services CCRx offers prospective clients is to assist them in the selection of a new pharmacy benefit manager, or PBM. Sometimes we are asked to utilize a Request for Proposal (RFP) process to narrow down the field of...
Effective Prior Authorization Management
Effective Prior Authorization Management August 2023 The effective management of the Prior Authorization (PA) function is a crucial aspect of healthcare that ensures patients receive the appropriate medications while controlling costs. Pharmacy Benefit Managers (PBMs)...
Conflict of Interest
Conflict of Interest July 2023 Recently a respected competitor published an article condemning most pharmacy benefit consultants for not disclosing conflicts of interest. They correctly pointed out that many big corporations such as “Boeing and UPS to local school...
New Transparency Models
New Transparency Models May 23, 2023 Both Express Scripts and OptumRx have announced new, optional Pass-Through pricing programs. Their clients can adopt this new pricing strategy, or they can continue with non-transparent pricing where the PBM won’t disclose the true...
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company April 2023 The Mark Cuban Cost Plus Drug Company has announced that they have entered into a contract with JanssenUS, a subsidiary of Johnson and Johnson, to distribute Invokana, an important...